Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

PBRM1 loss-of-function mutations and response to immune checkpoint blockade in clear cell renal cell carcinoma

Jake Conway, Amaro Taylor-Weiner, David Braun, Ziad Bakouny, Toni K. Choueiri, View ORCID ProfileEliezer M. Van Allen
doi: https://doi.org/10.1101/2020.10.30.20222356
Jake Conway
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2Biomedical Informatics and Genomics Program, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amaro Taylor-Weiner
2Biomedical Informatics and Genomics Program, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Braun
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ziad Bakouny
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toni K. Choueiri
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eliezer M. Van Allen
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eliezer M. Van Allen
  • For correspondence: eliezerm_vanallen@dfci.harvard.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

The biological role of PBRM1 loss-of-function (LOF) mutations mediating response to immune checkpoint blockade (ICB) in clear cell renal cell carcinoma (ccRCC) remains an area of active investigation. A recent study (hereafter, ‘the MSK study’) evaluated this hypothesis in a clinically heterogeneous single institution retrospective ccRCC cohort using targeted sequencing and did not find a univariable statistically significant association for PBRM1 LOF and time-to-treatment failure (TTF), but did report a significant association between continuous tumor mutational burden (TMB) and ICB TTF. We re-analyzed this cohort to (i) match the methodology from previous studies and (ii) account for differences in cohort development, statistical approaches, mutation classifications, and outcome measurements. Univariable analysis of the PBRM1 LOF mutation hypothesis, when performed analogously to prior studies, demonstrated a modest statistically significant association with TTF on ICB (p = 0.047; HR = 0.7, 95% CI = 0.49 - 0.99). By contrast, when using the different methodology presented in the MSK study, statistical modeling demonstrated that there was insufficient power to detect this association given the altered classification scheme and modest effect size. In addition, after appropriately normalizing TMB to account for anomalous outliers, TMB was not significantly associated with ICB response in ccRCC. Thus, this study provides further support for the biological association between PBRM1 LOF and favorable clinical outcomes on ICB in specific ccRCC clinical contexts. However, we again strongly caution against interpreting that this PBRM1 biological association, likely one of many modest mediators of tumor-immune-stromal interactions, achieves broadly generalizable predictive biomarker status for ICB in diverse clinical contexts. The PBRM1 LOF biological association has only been shown to be modestly predictive in the post-VEGF TKI ICB-monotherapy ccRCC patient population. Given emerging data about the biological role of PBRM1 in contributing to interwoven immune and angiogenesis programs (among many others), and the rapidly shifting therapeutic combination strategies invoking these processes in ccRCC, focused biological and predictive biomarker analyses in specific clinical settings using appropriately annotated clinical trial cohorts are necessary.

Competing Interest Statement

Advisory/Consulting: Tango Therapeutics, Genome Medical, Invitae, Enara Bio, Janssen, Manifold Bio, Monte Rosa Research support: Novartis, BMS Equity: Tango Therapeutics, Genome Medical, Syapse, Enara Bio, Manifold Bio, Microsoft, Monte Rosa Travel reimbursement: Roche/Genentech Patents: Institutional patents filed on chromatin mutations and immunotherapy response, and methods for clinical interpretation

Funding Statement

No external funding was received for this study

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study is reanalysis of publicly available data

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data (as provided by the corresponding author of the initiating study) and code written to perform the analyses presented herein is available at: https://github.com/vanallenlab/PBRM1_MSK_RCC_analysis

https://github.com/vanallenlab/PBRM1_MSK_RCC_analysis

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted November 04, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
PBRM1 loss-of-function mutations and response to immune checkpoint blockade in clear cell renal cell carcinoma
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
PBRM1 loss-of-function mutations and response to immune checkpoint blockade in clear cell renal cell carcinoma
Jake Conway, Amaro Taylor-Weiner, David Braun, Ziad Bakouny, Toni K. Choueiri, Eliezer M. Van Allen
medRxiv 2020.10.30.20222356; doi: https://doi.org/10.1101/2020.10.30.20222356
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
PBRM1 loss-of-function mutations and response to immune checkpoint blockade in clear cell renal cell carcinoma
Jake Conway, Amaro Taylor-Weiner, David Braun, Ziad Bakouny, Toni K. Choueiri, Eliezer M. Van Allen
medRxiv 2020.10.30.20222356; doi: https://doi.org/10.1101/2020.10.30.20222356

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (134)
  • Cardiovascular Medicine (1746)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (651)
  • Epidemiology (10770)
  • Forensic Medicine (8)
  • Gastroenterology (582)
  • Genetic and Genomic Medicine (2930)
  • Geriatric Medicine (286)
  • Health Economics (531)
  • Health Informatics (1917)
  • Health Policy (832)
  • Health Systems and Quality Improvement (741)
  • Hematology (290)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12495)
  • Intensive Care and Critical Care Medicine (684)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (319)
  • Neurology (2778)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (553)
  • Occupational and Environmental Health (596)
  • Oncology (1451)
  • Ophthalmology (440)
  • Orthopedics (172)
  • Otolaryngology (254)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (378)
  • Pediatrics (863)
  • Pharmacology and Therapeutics (361)
  • Primary Care Research (333)
  • Psychiatry and Clinical Psychology (2626)
  • Public and Global Health (5336)
  • Radiology and Imaging (1001)
  • Rehabilitation Medicine and Physical Therapy (592)
  • Respiratory Medicine (721)
  • Rheumatology (329)
  • Sexual and Reproductive Health (288)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (124)